Cartalax (20MG)

What Is Cartalax and Why Buy It for Research?

Buy Cartalax 20mg in Switzerland for research into cartilage biology, chondrocyte function, and tissue-specific gene regulation. Specifically, Cartalax (also known as AED, T-31, or AC-4) is a synthetic tripeptide composed of three amino acids with the sequence Ala-Glu-Asp (AED). It is the shortest of the commonly referenced Khavinson peptide bioregulators, consisting of only three amino acids. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology developed Cartalax as a cartilage- and bone-specific bioregulator.

In scientific research, Cartalax serves as a molecular tool for studying tissue-specific gene expression regulation in cartilage and connective-tissue experimental systems. Researchers consider this peptide particularly valuable for investigating chondrocyte proliferation, cartilage matrix formation, and musculoskeletal health. Furthermore, Core Peptides supplies Cartalax as a lyophilized powder in a 20mg format exclusively for laboratory use. Therefore, researchers seeking to source this compound for their work will find it readily available when they buy Cartalax 20mg in Switzerland.

Cartalax Research Overview: Buy Cartalax 20mg in Switzerland for Cartilage Studies

Centrally, research into Cartalax has focused on its function as a tissue-specific bioregulator targeting cartilage and connective tissue. Researchers identified the peptide through amino acid analysis of cartilage tissue extracts, where the AED sequence appeared as a recurring motif. Notably, the AED sequence matches a fragment found in the alpha-1 chain of type XI collagen, a structural protein critical for maintaining cartilage integrity and organizing the extracellular matrix. This structural homology provides a rational basis for the peptide’s reported tissue specificity.

Cartalax represents the Ala-Glu-Asp core sequence shared by several other Khavinson peptides—Epithalon (AEDG), Bronchogen (AEDL), and Cardiogen (AEDR) all contain AED as their first three amino acids. This overlap suggests that the AED core may have inherent biological activity that is further refined by a fourth amino acid to achieve organ specificity. Cartalax, as the tripeptide core alone, has been proposed to target cartilage and bone tissue specifically. Accordingly, researchers who buy Cartalax 20mg in Switzerland from Core Peptides can support their investigations into peptide-DNA interactions, chondrocyte biology, and musculoskeletal research.

How Does Cartalax Work in Research?

Mechanistically, Cartalax’s proposed action involves functioning as a nuclear-targeting peptide that modulates gene expression in cartilage and connective tissue cells. Multiple studies have shown that the main mechanism of action of such peptides is likely to be their ability to regulate gene expression and protein synthesis. Cartalax operates through the Khavinson bioregulator mechanism, with specific effects on chondrocyte biology, senescence pathways, and cartilage matrix metabolism.

In organotypic cartilage tissue cultures from both young (3-month) and old (24-month) rats, Cartalax stimulated chondrocyte proliferation, increasing the cartilage area index by 18-38%. The proliferative effect was mediated through upregulation of proliferating cell nuclear antigen (PCNA), a molecular marker of active cell division. Importantly, the effect persisted in aged tissue, suggesting that Cartalax can reactivate proliferative capacity in senescent chondrocytes.

Furthermore, research indicates that Cartalax reduces expression of key senescence markers in cell culture: p16INK4a by approximately 25%, p21WAF1 by approximately 25%, and p53. In chondrocyte and fibroblast cultures, researchers have used it to examine effects on cell proliferation, apoptosis, and expression of extracellular-matrix genes such as type II collagen and aggrecan. In molecular-docking work within the Khavinson model, researchers assign the AED motif to a specific promoter site, supporting its use as a research probe for putative short-peptide and DNA-promoter interactions.

Why Is Cartalax Studied in Switzerland?

Primarily, researchers study Cartalax because it represents a well-characterized tripeptide bioregulator that enables investigation of cartilage-specific gene expression, chondrocyte function, and musculoskeletal health. In fact, this compound offers a focused tool for studying the molecular mechanisms underlying cartilage maintenance, cellular senescence, and tissue repair.

Research has demonstrated Cartalax’s effects across multiple domains. In organotypic tissue culture, Cartalax stimulated chondrocyte proliferation and increased cartilage area index. Studies show that Cartalax reduces senescence markers p16, p21, and p53, modulating cellular aging pathways. Additionally, researchers have investigated Cartalax for its geroprotective effects on skin, cartilage, and kidney tissue. The peptide has demonstrated efficacy in animal models of osteoarthritis and in clinical studies with patients with osteoarthritis of older age groups. Ultimately, researchers who buy Cartalax 20mg in Switzerland gain access to a research tool that may help uncover mechanisms underlying cartilage biology, musculoskeletal health, and tissue-specific gene regulation.

Cartalax Research Areas in Laboratory Studies

Research Area	Focus	Evidence Level
Chondrocyte Proliferation	Cell cycle activation, cartilage area index, PCNA upregulation	Ex Vivo / Preclinical
Senescence Marker Reduction	p16INK4a, p21WAF1, p53 suppression, cellular aging pathways	Mechanistic / In Vitro
Cartilage Matrix Formation	Type II collagen, aggrecan expression, ECM remodeling	Mechanistic / In Vitro
Fibroblast Function	Skin fibroblast regulation, connective tissue maintenance	Mechanistic / In Vitro
DNA Interaction	Peptide-DNA binding, promoter site interaction, gene regulation	Mechanistic
Musculoskeletal Health	Cartilage maintenance, joint health, osteoarthritis models	Animal / Preclinical
Anti-Aging and Geroprotection	Age-related cartilage decline, cellular senescence reversal	Preclinical

Cartalax Compared With Related Research Compounds

Compound	Research Focus	Mechanism / Target	Key Difference
Cartalax (AED)	Cartilage, connective tissue, chondrocytes	DNA interaction, gene expression modulation	Tripeptide; cartilage-specific bioregulator
Epitalon (AEDG)	Pineal gland, aging, circadian rhythms	DNA interaction, telomerase activation	Different target tissue; Ala-Glu-Asp-Gly sequence
Bronchogen (AEDL)	Bronchial epithelium, pulmonary research	DNA interaction, gene expression modulation	Different target tissue; Ala-Glu-Asp-Leu sequence
Cardiogen (AEDR)	Cardiac tissue, cardiomyocyte function	DNA interaction, chromatin modulation	Different target tissue; Ala-Glu-Asp-Arg sequence

Comparatively, Cartalax differs from other Khavinson peptide bioregulators in its tissue specificity and peptide length. On the one hand, Epitalon (Ala-Glu-Asp-Gly), Bronchogen (Ala-Glu-Asp-Leu), and Cardiogen (Ala-Glu-Asp-Arg) are tetrapeptides with a fourth amino acid that confers organ specificity. On the other hand, Cartalax is the shortest of the Khavinson peptides, consisting of only three amino acids—the AED core sequence itself. As the tripeptide core, researchers propose Cartalax to target cartilage and bone tissue specifically. In contrast, the tetrapeptides have more refined organ specificity conferred by their fourth amino acid.

Research Applications for Cartalax in Switzerland

Scientists have investigated Cartalax across several research domains:

• Chondrocyte Biology Studies: Researchers use Cartalax to investigate chondrocyte proliferation, cartilage area index, and PCNA upregulation in organotypic tissue cultures from both young and aged animals.
• Senescence Research: The peptide serves as a tool for studying senescence marker reduction, including p16INK4a, p21WAF1, and p53 suppression in cell culture models.
• Cartilage Matrix Formation: Investigations have explored Cartalax’s effects on type II collagen and aggrecan expression, as well as extracellular matrix remodeling.
• Connective Tissue Research: Studies have examined Cartalax’s regulation of skin fibroblast function and connective tissue maintenance.
• DNA Interaction Studies: Molecular-docking work has investigated the AED motif’s interaction with specific promoter sites and short peptide-DNA interactions.
• Musculoskeletal Health Models: Preclinical research has examined Cartalax’s effects in osteoarthritis models and joint health studies.

Evidently, researchers who buy Cartalax 20mg in Switzerland gain a valuable addition to any laboratory toolkit focused on cartilage biology, musculoskeletal research, and tissue-specific peptide bioregulation.

Cartalax Product Specifications

Specification	Details
Product Name	Cartalax (AED)
Alternative Names	AED, T-31, AC-4, Ala-Glu-Asp, Cartalax peptide bioregulator
Amount	20mg
Form	Lyophilized powder (white to off-white)
Purity	Not verified (≥98-99% HPLC purity reported by some suppliers)
Amino Acid Sequence	H-Ala-Glu-Asp-OH (AED)
Sequence (3-letter)	Ala-Glu-Asp
Peptide Length	3 amino acids (tripeptide)
Molecular Formula	C₁₂H₁₉N₃O₈
Molecular Weight	333.30 g/mol
CAS Number	Not available
Research Category	Healing & Regeneration / Anti-Aging & Longevity
Research Use	Laboratory research use only
CoA	Available upon request (not verified)
Storage	Lyophilized powder should be stored desiccated at -20°C or below, protected from light
Solubility	Soluble in water and buffered aqueous solutions

How to Evaluate Cartalax Quality for Research

When sourcing Cartalax peptide for laboratory research, researchers should consider several quality indicators:

• Identity Confirmation: Analytical techniques such as mass spectrometry should confirm the compound’s molecular weight (333.30 g/mol) and sequence (H-Ala-Glu-Asp-OH).
• Purity Assessment: High-performance liquid chromatography (HPLC) should verify purity, with ≥98% considered standard for research-grade material.
• Batch Traceability: Lot numbers and batch information enable researchers to track specific production runs.
• Certificate of Analysis: A CoA should accompany the product, detailing analytical testing results including HPLC purity and identity confirmation.
• Labeling Accuracy: Proper labeling should clearly indicate the product name, amount (20mg), sequence, molecular formula, and storage recommendations.
• Storage Conditions: Appropriate storage at -20°C or below in desiccated, dark conditions helps maintain peptide stability.

Understanding the Certificate of Analysis

Typically, a Certificate of Analysis (CoA) accompanies research peptides and provides information about the specific batch’s analytical testing. For example, a CoA may include product identity confirmation, purity percentage as determined by HPLC, batch or lot number for traceability, analytical methods used (e.g., mass spectrometry, HPLC), and a physical description of the product.

Nevertheless, it is important to note that a CoA does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. Instead, it serves as a quality control document that helps researchers verify the identity and purity of the peptide they are using in their laboratory investigations.

Storage and Stability of Cartalax

Core Peptides supplies Cartalax as a lyophilized (freeze-dried) powder. To maintain stability and integrity:

• Store the lyophilized powder desiccated at -20°C or below for long-term storage
• Store at 4°C for short-term storage if frequent access is required
• Avoid repeated freeze-thaw cycles
• Weigh under dry conditions; the peptide is hygroscopic
• Reconstitute only immediately before use with appropriate sterile solvents (sterile water or buffered aqueous solutions)
• Inject solvent slowly against the inner wall of the vial; avoid vigorous agitation during dissolution
• Filter sterilize if required (e.g., 0.22 µm) immediately prior to use
• Aliquot and store reconstituted solutions at -20°C or below to minimize degradation
• Protect from light and moisture; prolonged exposure to light, elevated temperature, or aqueous environments may reduce stability

Frequently Asked Questions About Buying Cartalax 20mg in Switzerland

What is Cartalax?

Specifically, Cartalax (AED, T-31) is a synthetic tripeptide with the amino acid sequence Ala-Glu-Asp (AED). It is a tissue-specific bioregulator developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a cartilage- and bone-specific bioregulator.

What is Cartalax researched for?

Primarily, researchers study Cartalax for its role in cartilage tissue maintenance, chondrocyte proliferation, and musculoskeletal health. Studies have investigated its effects on senescence marker reduction, cartilage matrix formation, and fibroblast function.

How does Cartalax work?

Mechanistically, Cartalax functions through the Khavinson bioregulator mechanism, with specific effects on chondrocyte biology, senescence pathways, and cartilage matrix metabolism. The peptide stimulates chondrocyte proliferation through PCNA upregulation and reduces senescence markers p16, p21, and p53.

What is the molecular weight of Cartalax?

The molecular weight is 333.30 g/mol.

What is the molecular formula of Cartalax?

The molecular formula is C₁₂H₁₉N₃O₈.

What research exists on Cartalax?

Research on Cartalax includes organotypic tissue culture studies demonstrating chondrocyte proliferation (18-38% increase in cartilage area index) and PCNA upregulation, in vitro studies showing senescence marker reduction (p16, p21, p53 by approximately 25%), and preclinical studies in animal models of osteoarthritis.

Is Cartalax approved as a medicine?

No. Regulatory authorities have not approved Cartalax as a medicine, pharmaceutical, or therapeutic agent. All published research is preclinical.

Is Cartalax intended for human use?

No. Cartalax is intended for laboratory research use only and is not for human consumption, injection, or therapeutic application.

Where can I buy Cartalax 20mg in Switzerland?

You can buy Cartalax 20mg in Switzerland from Core Peptides, a trusted research peptide supplier serving the Swiss scientific community.

How should researchers evaluate Cartalax quality?

Researchers should look for identity confirmation via mass spectrometry, purity data from HPLC, batch traceability, and a Certificate of Analysis.

Related Research Compounds

Researchers interested in Cartalax may also find the following related compounds relevant to their work:

• Epitalon — A related Khavinson tetrapeptide (Ala-Glu-Asp-Gly) researched for pineal gland function, aging, and telomerase activation.
• Bronchogen — A related Khavinson tetrapeptide (Ala-Glu-Asp-Leu) researched for bronchial epithelium and pulmonary tissue.
• Cardiogen — A related Khavinson tetrapeptide (Ala-Glu-Asp-Arg) researched for cardiac tissue and cardiomyocyte function.
• BPC-157 — A peptide researched for tissue healing, gastrointestinal protection, and angiogenesis.

Explore Healing & Regeneration

Cartalax belongs to the Healing & Regeneration category of research compounds. Healing & Regeneration products are studied for their potential roles in tissue repair, cartilage maintenance, and regenerative mechanisms. Generally, researchers who buy Cartalax 20mg in Switzerland often pair it with related compounds in this category to explore complementary pathways in cartilage biology and musculoskeletal research.

Explore Anti-Aging & Longevity

Researchers studying age-related cartilage decline, cellular senescence, and tissue-specific bioregulation may also find relevant compounds in the Anti-Aging & Longevity category. Cartalax’s effects on senescence marker reduction and chondrocyte proliferation in aged tissue models make it a valuable tool for investigating cartilage aging and regenerative biology.

Further Research

For researchers seeking to deepen their understanding of Cartalax and its research applications, the following areas may warrant further investigation:

• The relationship between Cartalax-mediated DNA interaction and specific downstream gene expression changes in chondrocytes and fibroblasts
• Comparative studies between Cartalax and other Khavinson peptides in various cartilage and tissue-specific models
• The potential role of Cartalax in modulating age-related cartilage function decline and cellular senescence
• Mechanistic studies on Cartalax’s interaction with the AED core sequence and its functional consequences for gene transcription
• Exploration of Cartalax’s effects on different cell types and tissue systems beyond cartilage and connective tissue

Research Disclaimer

Researchers must not use it for human consumption, injection, or any form of therapeutic application. Moreover, this product is not a medicine, pharmaceutical, or medical device. Furthermore, Swissmedic, the FDA, EMA, or any other regulatory authority have not approved it for human use. Researchers should consult Swissmedic for applicable regulations and guidance on research peptide handling in Switzerland.

Generally, the information provided on this page is for educational and scientific reference purposes only. Therefore, it does not constitute medical advice, treatment recommendations, or dosing instructions. Ultimately, researchers bear the responsibility for ensuring that their use of this product complies with all applicable laws, regulations, and institutional guidelines.